Opinion|Videos|April 4, 2025
Communicating With Patients on the Safety of JAK Inhibitors in Atopic Dermatitis
Experts discuss how to effectively communicate the safety of JAK inhibitors to patients with atopic dermatitis, including how to address the FDA boxed warning by emphasizing the balance of risks and benefits and tailoring the conversation based on individual patient concerns and risk factors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you talk to your patients about the safety of JAK inhibitors in atopic dermatitis? How do you navigate the discussion regarding the boxed warning?
Advertisement
Related to this article
Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.
Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
In 3-year BE HEARD data, close to half of bimekizumab-treated HS patients reported no quality-of-life impact, regardless of baseline draining tunnel count.
Autumn Burnette, MD, hosts a new monthly allergy and immunology podcast from HCPLive, opening with an episode on hereditary angioedema.
Martina Porter, MD, of Beth Israel Deaconess Medical Center discusses unmet needs in HS and where oral povorcitinib fits among emerging options.
Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
Advertisement
Advertisement
Trending on HCPLive
1
Zabopegdutide Improves Fibrosis, MASH Resolution at 48 Weeks
2
Asundexian Receives FDA Approval for Secondary Stroke Prevention
3
RNA Editing With WVE-006 Restores Functional AAT, Cuts Z-AAT in AATD
4
Efinopegdutide Improves MASH Resolution, Fibrosis in Phase 2b Trial
5